<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatitis C virus infection in kidney donors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatitis C virus infection in kidney donors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatitis C virus infection in kidney donors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marion Muche, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seema Baid-Agrawal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transplantation of a kidney from a donor with hepatitis C virus (HCV) infection may cause HCV infection in the recipient. Untreated HCV infection has been associated with increased morbidity and possibly mortality in kidney transplant recipients. However, the widespread availability of highly effective direct-acting antiviral (DAA) therapies has opened the possibility of curing HCV infection, even after transplantation, and thereby attenuating the negative impact of receiving a kidney from a donor with HCV infection.</p><p>This topic reviews issues surrounding deceased or living kidney donors with HCV infection. HCV infection in kidney transplant recipients, transplant candidates, and nontransplant candidate patients on dialysis is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1861.html" rel="external">"Hepatitis C virus infection in patients on maintenance dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H2785524878"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4080455096"><span class="h2">Prevalence of HCV among donors</span><span class="headingEndMark"> — </span>In the United States, the prevalence of HCV infection among deceased organ donors has increased as a result of the ongoing opioid crisis. An analysis of 70,414 deceased organ donors in the United States from 2010 to 2017 using the Organ Procurement and Transplantation Network (OPTN) database reported an overall increase in the prevalence of anti-HCV positivity (4.2 to 7.3 percent from 2010 to 2017) and HCV ribonucleic acid (RNA) positivity (3.9 to 4.9 percent from 2014 to 2017) [<a href="#rid1">1</a>]. While rates of both anti-HCV positivity and HCV RNA positivity increased among increased-risk donors (from 15.9 to 21.6 percent and from 8.6 to 15.7 percent, respectively), they decreased among standard-risk donors (from 3 to 2.2 percent and from 2.2 to 1.1 percent, respectively). </p><p>By comparison, the prevalence of HCV among kidney donors is much lower in other countries, ranging from 0.3 percent in the United Kingdom (between 2009 and 2016) [<a href="#rid2">2</a>], 0.9 percent in Germany (between 2017 and 2019) [<a href="#rid3">3</a>], to 2.2 percent in Australia (between 2014 and 2020) [<a href="#rid4">4</a>]. In many Asian countries, anti-HCV positive kidney donors are generally uncommon [<a href="#rid5">5</a>]. There are scarce data on HCV prevalence in organ donors available from any of the African countries performing organ transplantation. </p><p class="headingAnchor" id="H3888514567"><span class="h2">Risk of transmission</span><span class="headingEndMark"> — </span>The risk of HCV transmission through kidney transplantation depends on the presence or absence of HCV RNA (ie, HCV viremia) in the donor.</p><p class="headingAnchor" id="H310295922"><span class="h3">From HCV RNA–positive donors</span><span class="headingEndMark"> — </span>Donors who are positive for HCV RNA have active viremia, which poses a high risk of transmission through transplantation. Among studies of patients without HCV infection who received a kidney from a donor with HCV viremia and did not receive direct-acting antiviral (DAA) therapy before evaluation for posttransplant HCV, viremia was detected in 77 to 100 percent [<a href="#rid6">6-11</a>]. (See <a class="local">'Approach'</a> below.)</p><p class="headingAnchor" id="H1164745793"><span class="h3">From HCV RNA–negative donors</span><span class="headingEndMark"> — </span>Donors who have detectable HCV antibody but are HCV RNA–negative are considered to have cleared the infection (either spontaneously or through antiviral treatment) and do not have active viremia. The risk of transmission of HCV from such patients is extremely low [<a href="#rid12">12-14</a>]. In general, kidney transplantation from such donors is considered a safe approach.</p><p>Although seroconversion (developing detectable HCV antibody) has been reported in recipients of kidneys from donors who were HCV antibody positive but HCV RNA negative, those recipients did not subsequently develop HCV viremia [<a href="#rid12">12,14</a>]. Thus, although HCV antibody was transmitted, HCV infection was not.</p><p>However, rare transmission of HCV from donors who were negative for HCV RNA at the time of organ procurement has been documented, likely because of false-negative HCV RNA results [<a href="#rid15">15,16</a>]. In one analysis of nine such donors associated with new HCV infection in recipients, eight were classified as increased-risk donors; one donor was not initially classified as an increased-risk donor but had evidence of injection drug use in the medical record [<a href="#rid16">16</a>]. Two donors tested positive for HCV RNA from stored specimens during investigation of donor-derived HCV infection.</p><p class="headingAnchor" id="H1402490396"><span class="h1">EVALUATION FOR HCV INFECTION AMONG DONORS</span><span class="headingEndMark"> — </span>Prior to transplantation, the potential donor should be evaluated for evidence of HCV infection by blood tests (including assays for anti-HCV antibody and HCV RNA according to the United Network for Organ Sharing [UNOS]) and for the risk of HCV infection based on environmental or lifestyle factors. </p><p>The approach to evaluating for HCV infection or risk of infection varies slightly between deceased and living donors.</p><p class="headingAnchor" id="H434021539"><span class="h2">Deceased donors</span><span class="headingEndMark"> — </span>Most organ procurement organizations (OPOs) have a policy for testing all deceased organ donors for evidence of HCV infection. In the United States, the screening of deceased donors is regulated by the Public Health Service (PHS) through the Organ Procurement and Transplantation Network (OPTN). The PHS issued guidelines for screening deceased donors for HCV in 2020 [<a href="#rid17">17</a>]. The screening process includes an assessment of risk criteria associated with HCV infection and blood tests that indicate previous or current HCV infection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of risk criteria associated with HCV infection</strong> – This is done through confidential interviews with next of kin, a life partner, a cohabitant, or a primary treating clinician. Risk criteria are listed in the table  (<a class="graphic graphic_table graphicRef121571" href="/z/d/graphic/121571.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood tests</strong> – All deceased donors should be tested for the presence of anti-HCV antibodies and for HCV RNA (by nucleic acid testing) within 96 hours before procurement of the kidney [<a href="#rid18">18</a>]. To ensure accuracy, testing should be performed on donor blood that is not hemodiluted (as among deceased donors who received blood products or crystalloid prior to death). (See  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Initial testing'</a> and  <a class="medical medical_review" href="/z/d/html/114280.html" rel="external">"Evaluation of the potential deceased organ donor (adult)", section on 'Infectious disease testing'</a>.) </p><p></p><p class="bulletIndent1">Test results should be made available prior to transplantation. Although the HCV RNA result may not be known prior to transplant, data may be subsequently used to guide treatment of the recipient. The OPO is advised to archive blood samples for at least 10 years. </p><p></p><p class="bulletIndent1">Both antibody and HCV RNA testing are important for evaluation. The immunoassay tests for HCV antibodies only detect evidence of prior infection. This test does not indicate whether active transmissible infection is present, which is indicated by a positive HCV RNA test. False-positive immunoassays are also possible, but the contemporary tests used for donor screening are more sensitive and specific than earlier tests and minimize the rate of false-positive antibody results [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">However, immunoassays may not identify donors who were recently infected (ie, within eight weeks prior to death), since it takes at least eight weeks for detectable antibodies to develop [<a href="#rid20">20</a>]. HCV RNA testing closes the window of a false-negative anti-HCV antibody result in the early phase of HCV infection. The average window period between exposure and HCV RNA detectability is approximately three to five days, and the estimated risk for undetected HCV infection has been reported to be less than 1 per million donors after seven days from the time of most recent potential exposure to the day of a negative RNA test [<a href="#rid16">16</a>]. HCV RNA testing is mandatory in the United States but may not yield a result quickly enough to be useful for the valuation of deceased donors with an unknown status of HCV infection [<a href="#rid21">21</a>]. HCV RNA testing can be falsely negative in infected, deceased individuals who received blood products or crystalloid just prior to death, or who became infected just before death, since HCV first replicates in target cells (ie, hepatocytes) before it appears in blood [<a href="#rid17">17</a>]. A single negative HCV RNA test may thus not exclude the possibility of HCV infection and transmission risk [<a href="#rid12">12,16,22</a>]. </p><p></p><p class="bulletIndent1">If a deceased donor is identified as being at risk for or known to have HCV infection, the OPO should notify both the OPTN and transplant center. The transplant center team should include this information in discussion of risk with the transplant candidate or medical decision maker. However, donors with HCV infection are not excluded from donation. (See <a class="local">'Use of kidneys from donors with HCV infection'</a> below.)</p><p></p><p class="headingAnchor" id="H1548494635"><span class="h2">Living donors</span><span class="headingEndMark"> — </span>The screening of living potential donors is closely regulated by PHS/OPTN in the United States. (See  <a class="medical medical_review" href="/z/d/html/7315.html" rel="external">"Kidney transplantation in adults: Evaluation of the living kidney donor candidate", section on 'Medical evaluation'</a>.)</p><p>As per the 2020 PHS guidelines, all living-donor candidates should be interviewed regarding risk criteria  (<a class="graphic graphic_table graphicRef121571" href="/z/d/graphic/121571.html" rel="external">table 1</a>). (See <a class="local">'Deceased donors'</a> above.)</p><p>All living-donor candidates should be tested for anti-HCV antibodies and for HCV RNA. The tests should be performed within at least 28 days prior to surgery and as close to the time of surgery as possible. If an HCV RNA–positive donor is identified, the transplant center should be notified and risk discussed with the potential recipient. If a kidney from an HCV RNA–positive donor is used, OPTN should be notified. </p><p>HCV RNA–positive living donors should be assessed for liver fibrosis, as the presence and extent of fibrosis may impact their eligibility to donate a kidney. While liver disease is not defined as an absolute contraindication by OPTN, it may be a relative contraindication beyond OPTN requirements at some centers. The presence of significant liver disease with synthetic and functional abnormalities is considered an absolute contraindication for donation. (See  <a class="medical medical_review" href="/z/d/html/1239.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"</a>.)</p><p>HCV RNA–positive living donors who do not have evidence of liver fibrosis may be acceptable for kidney donation. For such living donors, we suggest antiviral therapy prior to transplantation rather than after transplantation. The vast majority of HCV infections can be successfully treated with short (8- to 12-week) direct-acting antiviral (DAA) regimens. Successful antiviral treatment results in sustained virologic response at 12 weeks, which is considered a marker for cure of HCV infection. If transplantation cannot be delayed for the 8 to 12 weeks of treatment and if a timely transplant would be highly beneficial for the recipient, antiviral treatment can be delayed until after transplantation. This approach is largely consistent with the 2022 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [<a href="#rid23">23</a>]. The selection of a DAA regimen is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a>.)</p><p class="headingAnchor" id="H4089166089"><span class="h1">USE OF KIDNEYS FROM DONORS WITH HCV INFECTION</span></p><p class="headingAnchor" id="H2162891870"><span class="h2">Approach</span><span class="headingEndMark"> — </span>When an eligible kidney becomes available from a donor with HCV viremia, potential options for the transplant candidate include proceeding with transplantation with early direct-acting antiviral (DAA) therapy versus remaining on the wait list. For transplant candidates (regardless of their HCV status) who can receive DAA therapy posttransplant, we suggest proceeding with transplantation. This is consistent with the 2022 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which recommend that kidneys from donors with HCV infection be considered regardless of the HCV status of the transplant recipients, provided that national or regional laws and regulations allow this practice and that the recipient is guaranteed DAA therapy in the early posttransplant period [<a href="#rid23">23</a>]. In all such cases, the recipient should receive detailed information about the advantages and potential risks of transplantation in order to provide informed consent. Policies on use of HCV RNA–positive organs vary by country and institution. (See <a class="local">'Institutional policies'</a> below and <a class="local">'Advantages'</a> below and <a class="local">'Potential risks'</a> below.)</p><p>The precise timing of antiviral therapy in the setting of kidney transplantation from an HCV viremic donor is uncertain and varies by institution. In the United States, the joint guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend that antiviral therapy be initiated immediately pretransplant, on the day of transplant, or within the first week posttransplant, as soon as the patient is clinically stable [<a href="#rid24">24</a>]. In some locations, antiviral therapy can only be started once HCV viremia has been confirmed in the recipient; in those cases, antiviral therapy as early as possible posttransplant is also recommended.</p><p>Since the HCV genotype of the donor is often unknown, we recommend a pangenotypic antiviral regimen for recipients of HCV RNA–positive kidneys. The optimal duration in this setting is also uncertain; the joint AASLD/IDSA guidelines recommend [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> for 12 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> for 8 weeks if administered within the first week after transplant or 12 weeks if administered later. In contrast to the AASLD/IDSA guidelines, we suggest glecaprevir-pibrentasvir for 8 weeks unless treatment is postponed for more than three months posttransplant, in which case we suggest 12 weeks, in accordance with European guidelines [<a href="#rid25">25</a>]. In some locations, payers may not cover glecaprevir-pibrentasvir for a full 12 weeks, which limits access to this regimen. Use of glecaprevir-pibrentasvir may also be limited by potential interactions with immunosuppressive agents  (<a class="graphic graphic_table graphicRef118768" href="/z/d/graphic/118768.html" rel="external">table 2</a>) and is contraindicated in patients with decompensated cirrhosis (Child-Pugh score B or C). (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'Interactions with immunosuppressive agents'</a>.)</p><p></p><p>Multiple studies have demonstrated the safety of transplanting kidneys from deceased donors with HCV into recipients without HCV when the recipient is treated with early or preemptive DAA therapy [<a href="#rid6">6-8,26-35</a>], supporting the use of kidneys from donors with HCV infection in patients without infection. Early trials found that the administration of <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> for 12 weeks, either initiated prophylactically (first dose given pretransplant) or upon detection of HCV RNA after transplantation, prevented chronic HCV infection in all recipients, and patients maintained overall good kidney allograft function without experiencing acute rejection [<a href="#rid6">6,26-28</a>]. Subsequent studies have reported successful transplantation with the use of other DAA regimens (eg, <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>, and sofosbuvir-ledipasvir) and with shorter durations of treatment (eg, four or eight weeks) with DAA therapy [<a href="#rid7">7,8,29-31,33,34</a>]. However, antiviral prophylaxis alone prior to transplant is not sufficient to prevent transmission; in studies where the antiviral regimen was initiated prior to transplantation, the rate of HCV viremia in the few days after transplant ranged from 0 to 88 percent [<a href="#rid26">26,28,30,31</a>]. Thus, a treatment course of antiviral therapy is generally used.</p><p>Observational data also suggest that kidney function and rates of rejection at one year and graft survival at five years are similar for recipients of HCV RNA–positive and HCV RNA–negative deceased-donor kidneys [<a href="#rid36">36-38</a>]. The results of these studies suggest that transplantation of HCV RNA–positive kidneys into HCV RNA–negative recipients, in conjunction with DAA therapy, could provide well-functioning allografts and cure HCV infection. Additional studies are required to assess the optimal timing of DAA treatment, long-term graft and patient outcomes, and potential risks of transplanting HCV RNA–positive kidneys into HCV RNA–negative recipients. </p><p>The safety of transplanting a kidney from an HCV antibody–positive living donor who has undergone successful antiviral treatment into an HCV-negative recipient or into an HCV RNA–positive recipient with a different HCV genotype is unknown, as data are limited [<a href="#rid39">39</a>]. However, extrapolating from data on transplantation of anti-HCV antibody–positive/HCV RNA–negative deceased-donor organs into HCV-negative recipients, the risk seems to be low. </p><p class="headingAnchor" id="H3522411690"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>The use of HCV RNA–positive kidneys could help expand the donor pool and reduce the waiting time for receiving a kidney transplant. Kidneys from deceased donors with HCV are presently an underused resource [<a href="#rid40">40-42</a>], and the use of such kidneys could help reduce wasting these organs. Although the discard rate of HCV RNA–positive kidneys is decreasing, it continues to be higher than that of kidneys from donors without HCV [<a href="#rid43">43-45</a>]. Discarded kidneys from HCV RNA–positive donors are more likely to be from younger donors with a lower kidney-donor profile index compared with kidneys from discarded kidneys from donors without HCV [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/7337.html" rel="external">"Kidney transplantation in adults: Organ sharing", section on 'Kidney donor profile index (KDPI)'</a>.)</p><p>Data on long-term graft and patient outcomes following transplantation of HCV RNA–positive kidneys in the DAA-therapy era are limited (see <a class="local">'Approach'</a> above). However, even before the introduction of DAA therapy, there appeared to be a survival advantage associated with receiving a kidney from an HCV-seropositive donor compared with remaining on the deceased-donor waitlist [<a href="#rid46">46-48</a>]. Among nearly 40,000 United States Renal Data System (USRDS) patients awaiting transplantation, transplantation with such a kidney was associated with improved survival versus remaining on a transplant waitlist (adjusted hazard ratio 0.76) [<a href="#rid46">46</a>]. These results were supported by another retrospective analysis of data from the national Organ Procurement and Transplant Network (OPTN) registry from 1994 to 2014 [<a href="#rid48">48</a>]. In this study, although five-year graft and patient survival were worse among HCV-seronegative recipients receiving HCV-seropositive kidneys compared with those receiving HCV-seronegative kidneys, the five-year patient survival from the time of waitlisting was superior when compared with waitlisted controls. One limitation of these data is that they did not distinguish survival outcomes among recipients of HCV-seropositive but RNA-negative kidneys versus recipients of HCV-seropositive and RNA-positive kidneys.</p><p class="headingAnchor" id="H3055795991"><span class="h2">Potential risks</span></p><p class="headingAnchor" id="H2132661631"><span class="h3">Recipients without HCV</span><span class="headingEndMark"> — </span>Transplantation of an HCV RNA–positive kidney is associated with a high risk of viral transmission from the donor to the recipient. However, this risk can be mitigated by early or preemptive treatment of the recipient with DAA therapy. (See <a class="local">'Risk of transmission'</a> above and <a class="local">'Approach'</a> above.)</p><p>A delay in initiation of DAA therapy may be associated with an increased incidence of cytomegalovirus and BK polyomavirus viremia, de novo donor-specific antibodies, and fibrosing cholestatic hepatitis [<a href="#rid7">7,8</a>]. These unexpected consequences may be seen in the real-world setting, where it often may not be possible to initiate preemptive/early therapy, as access to DAA therapy may be complicated by issues with insurance approval or lack of resources. Thus, any center performing kidney transplantation from an HCV RNA–positive donor to an HCV-negative recipient should confirm availability of DAA therapy in the early posttransplant period [<a href="#rid23">23</a>].</p><p>Prior to the advent of DAA therapy in 2014, when HCV could not be easily treated posttransplant, receipt of an HCV-seropositive kidney rather than an HCV-seronegative kidney was associated with increased morbidity, decreased survival, and higher rates of liver disease among HCV-seronegative recipients [<a href="#rid47">47,49,50</a>]. Cure of HCV infection could only be achieved by the administration of interferon-alpha, which had low response rates and was contraindicated after kidney transplantation. Thus, kidneys from donors with HCV were almost exclusively transplanted into recipients with HCV infection. </p><p class="headingAnchor" id="H3766784719"><span class="h3">Recipients with HCV</span><span class="headingEndMark"> — </span>Even in the absence of DAA therapy, it is uncertain whether transplanting a kidney from an HCV RNA–positive donor into a recipient with preexisting, untreated HCV infection is associated with additional risk. Most data come from the era prior to mandatory HCV RNA testing, when HCV positivity was defined only by HCV seropositivity, without consideration of the patient's viremic status. Such studies suggested that morbidity and mortality of HCV-seropositive recipients were not increased by the transplantation of kidneys from HCV-seropositive donors, despite the possibility of superinfection with HCV [<a href="#rid51">51-57</a>]. One report of 468 HCV-seropositive recipients found comparable 5- and 10-year survival rates between recipients of kidneys from HCV-seropositive and HCV-seronegative donors [<a href="#rid54">54</a>]. Graft survival also appeared comparable; in a case-control study of 205 HCV RNA–negative kidneys transplanted between 2014 and 2016, graft survival of the HCV-seropositive/RNA-negative kidneys transplanted in mostly HCV-seropositive recipients was similar to that of HCV-seronegative kidneys [<a href="#rid58">58</a>]. </p><p>By contrast, other single-center as well as large registry studies have shown increased mortality, graft loss, and adverse liver outcomes associated with the transplantation of HCV-seropositive kidneys in HCV-seropositive recipients [<a href="#rid59">59-62</a>]. Differences in immunosuppression or superinfection with another genotype may have explained the observed differences in outcomes in different studies. Furthermore, most of these studies tested only for anti-HCV antibodies but not for HCV RNA in both donors and recipients, which could further contribute to the observed differences. As an example, it is possible that some HCV-seropositive recipients may not have had chronic HCV infection at the time of transplant or that some kidneys were seropositive but HCV RNA negative and so had minimal risk of transmitting HCV. </p><p class="headingAnchor" id="H3666188328"><span class="h2">Institutional policies</span><span class="headingEndMark"> — </span>While kidney transplantation using HCV RNA–positive donors is slowly increasing, institutional practices and policies regarding the use of kidneys from HCV RNA–positive donors vary among transplant centers in the United States and around the world. Many centers do not perform kidney transplantation using HCV RNA–positive donors, whereas some centers may only allow transplantation of HCV RNA–positive kidneys into recipients with HCV [<a href="#rid43">43,63-65</a>].</p><p class="headingAnchor" id="H76564380"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113623.html" rel="external">"Society guideline links: Hepatitis C infection in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H2358683782"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Transplantation of a kidney from a donor with hepatitis C virus (HCV) infection may cause HCV infection in the recipient. Untreated HCV infection has been associated with increased morbidity and possibly mortality in kidney transplant recipients. However, the widespread availability of highly effective direct-acting antiviral (DAA) therapies has opened the possibility of curing HCV infection, even after transplantation, and thereby attenuating the negative impact of receiving a kidney from a donor with HCV infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of transmission </strong>– The risk of HCV transmission through kidney transplantation depends on the presence of HCV RNA (ie, HCV viremia) in the donor. Donors who are HCV RNA positive have active viremia, which poses a high risk of transmission through transplantation. By contrast, the risk of HCV transmission from patients who are HCV RNA negative is extremely low. (See <a class="local">'Risk of transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor evaluation for HCV infection </strong>– Prior to transplantation, the potential donor should be evaluated for evidence of HCV infection by blood tests (including assays for anti-HCV antibody and HCV RNA according to the United Network for Organ Sharing [UNOS]) and for the risk of HCV infection based on environmental or lifestyle factors. The approach to evaluation varies slightly between deceased and living donors. The potential recipient must be informed of the donor HCV status and the potential risk of infection prior to transplantation. (See <a class="local">'Evaluation for HCV infection among donors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of kidneys from donors with HCV infection </strong>– When an eligible kidney becomes available from a donor with HCV viremia, potential options for the transplant candidate include proceeding with transplantation with early DAA therapy versus remaining on the wait list. For transplant candidates (regardless of their HCV status) who can receive DAA therapy posttransplant, we suggest proceeding with transplantation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Early DAA therapy involves administration of a pangenotypic antiviral regimen (either <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> or <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>) as soon as possible after transplant (ideally within the first week). </p><p></p><p class="bulletIndent1">In all such cases, the recipient should receive detailed information about the advantages and potential risks of transplantation in order to provide informed consent. (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Institutional policies </strong>– While kidney transplantation using HCV RNA–positive donors is slowly increasing, institutional practices and policies regarding the use of kidneys from HCV RNA–positive donors vary among transplant centers in the United States and around the world. Many centers do not perform kidney transplantation using HCV RNA–positive donors, whereas some centers may only allow transplantation of HCV RNA–positive kidneys into recipients with HCV. (See <a class="local">'Institutional policies'</a> above.)</p><p></p><p class="headingAnchor" id="H1574741202"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Svetlozar Natov, MD, and Brian JG Pereira, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abara WE, Collier MG, Moorman A, et al. Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses - United States, 2010-2017. MMWR Morb Mortal Wkly Rep 2019; 68:61.</a></li><li><a class="nounderline abstract_t">Trotter PB, Summers DM, Ushiro-Lumb I, et al. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives? Transplantation 2018; 102:664.</a></li><li><a class="nounderline abstract_t">Duerr M, Liefeldt L, Friedersdorff F, et al. Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. J Clin Med 2020; 10.</a></li><li><a class="nounderline abstract_t">Dutch MJ, Patrick CJ, Boan PA, et al. Prevalence of Blood-Borne Viruses and Predictors of Risk in Potential Organ Donors in Australia. Transpl Int 2022; 35:10395.</a></li><li><a class="nounderline abstract_t">Li PK, Bavanandan S, Mohamed R, et al. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney Int Rep 2020; 5:1129.</a></li><li><a class="nounderline abstract_t">Goldberg DS, Abt PL, Blumberg EA, et al. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. N Engl J Med 2017; 376:2394.</a></li><li><a class="nounderline abstract_t">Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. Am J Transplant 2019; 19:3046.</a></li><li><a class="nounderline abstract_t">Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience. Hepatology 2020; 72:32.</a></li><li><a class="nounderline abstract_t">Friebus-Kardash J, Gäckler A, Kribben A, et al. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. Transpl Infect Dis 2019; 21:e13146.</a></li><li><a class="nounderline abstract_t">Jandovitz N, Nair V, Grodstein E, et al. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience. Transpl Infect Dis 2021; 23:e13540.</a></li><li><a class="nounderline abstract_t">Terrault NA, Burton J, Ghobrial M, et al. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology 2021; 73:2110.</a></li><li><a class="nounderline abstract_t">Dao A, Cuffy M, Kaiser TE, et al. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool. Clin Transplant 2019; 33:e13598.</a></li><li><a class="nounderline abstract_t">Nowak KM, Witzke O, Sotiropoulos GC, et al. Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. Kidney Int Rep 2017; 2:53.</a></li><li><a class="nounderline abstract_t">de Vera ME, Volk ML, Ncube Z, et al. Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant 2018; 18:2451.</a></li><li><a class="nounderline abstract_t">Suryaprasad A, Basavaraju SV, Hocevar SN, et al. Transmission of Hepatitis C Virus From Organ Donors Despite Nucleic Acid Test Screening. Am J Transplant 2015; 15:1827.</a></li><li><a class="nounderline abstract_t">Bixler D, Annambholta P, Abara WE, et al. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017. Am J Transplant 2019; 19:2570.</a></li><li><a class="nounderline abstract_t">Jones JM, Kracalik I, Levi ME, et al. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Schillie S, Wester C, Osborne M, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Preiksaitis JK, Cockfield SM, Fenton JM, et al. Serologic responses to hepatitis C virus in solid organ transplant recipients. Transplantation 1997; 64:1775.</a></li><li><a class="nounderline abstract_t">Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant 2014; 14:2206.</a></li><li><a class="nounderline abstract_t">Challine D, Pellegrin B, Bouvier-Alias M, et al. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004; 364:1611.</a></li><li><a class="nounderline abstract_t">Shah AP, Cameron A, Singh P, et al. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022; 102:S129.</a></li><li class="breakAll">Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on July 01, 2023).</li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="2e4b4f5d42414848474d4b6e4b4f5d42414848474d4b004b5b">[email protected]</span>, Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative:, Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol 2020; 73:1170.</a></li><li><a class="nounderline abstract_t">Durand CM, Bowring MG, Brown DM, et al. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med 2018; 168:533.</a></li><li><a class="nounderline abstract_t">Reese PP, Abt PL, Blumberg EA, et al. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Ann Intern Med 2018; 169:273.</a></li><li><a class="nounderline abstract_t">Sise ME, Strohbehn IA, Chute DF, et al. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep 2020; 5:459.</a></li><li><a class="nounderline abstract_t">Franco A, Moreso F, Merino E, et al. Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study. Transpl Int 2019; 32:710.</a></li><li><a class="nounderline abstract_t">Durand CM, Barnaba B, Yu S, et al. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study. Ann Intern Med 2021; 174:137.</a></li><li><a class="nounderline abstract_t">Sise ME, Goldberg DS, Kort JJ, et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol 2020; 31:2678.</a></li><li><a class="nounderline abstract_t">Feng Z, Zhang J, Tan W, et al. Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis. Front Med (Lausanne) 2022; 9:802686.</a></li><li><a class="nounderline abstract_t">Gupta G, Yakubu I, Zhang Y, et al. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transplant 2021; 21:3734.</a></li><li><a class="nounderline abstract_t">Gupta G, Yakubu I, Bhati CS, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant 2020; 20:739.</a></li><li><a class="nounderline abstract_t">Potluri V, Naqvi F, Goldberg DS, et al. Longer-Term Clinical Outcomes From the THINKER and EXPANDER Trials of Transplantation of HCV-RNA+ Donor Kidneys Into Hepatitis C Virus-Negative Recipients. Kidney Int Rep 2023; 8:1460.</a></li><li><a class="nounderline abstract_t">Molnar MZ, Azhar A, Tsujita M, et al. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes. Am J Kidney Dis 2021; 77:739.</a></li><li><a class="nounderline abstract_t">Schaubel DE, Tran AH, Abt PL, et al. Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era. JAMA 2022; 328:1102.</a></li><li><a class="nounderline abstract_t">Molnar MZ, Potluri VS, Schaubel DE, et al. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant 2022; 22:599.</a></li><li><a class="nounderline abstract_t">Cruzado JM, Gil-Vernet S, Castellote J, et al. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant 2013; 13:2773.</a></li><li><a class="nounderline abstract_t">Kling CE, Perkins JD, Landis CS, et al. Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change. Am J Transplant 2017; 17:2863.</a></li><li><a class="nounderline abstract_t">Goldberg DS, Blumberg E, McCauley M, et al. Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic. Am J Transplant 2016; 16:2836.</a></li><li><a class="nounderline abstract_t">Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting Hepatitis C-Positive Kidneys. N Engl J Med 2015; 373:303.</a></li><li><a class="nounderline abstract_t">Potluri VS, Goldberg DS, Mohan S, et al. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol 2019; 30:1939.</a></li><li><a class="nounderline abstract_t">Durand CM, Bowring MG, Thomas AG, et al. The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Ann Intern Med 2018; 168:702.</a></li><li><a class="nounderline abstract_t">Ariyamuthu VK, Sandikci B, AbdulRahim N, et al. Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard. Transpl Infect Dis 2020; 22:e13204.</a></li><li><a class="nounderline abstract_t">Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4:2032.</a></li><li><a class="nounderline abstract_t">Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13:2974.</a></li><li><a class="nounderline abstract_t">Gupta G, Kang L, Yu JW, et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data. Clin Transplant 2017; 31.</a></li><li><a class="nounderline abstract_t">Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345:484.</a></li><li><a class="nounderline abstract_t">Bouthot BA, Murthy BV, Schmid CH, et al. Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement. Transplantation 1997; 63:849.</a></li><li><a class="nounderline abstract_t">Natov SN, Lau JY, Ruthazer R, et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1999; 56:700.</a></li><li><a class="nounderline abstract_t">Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47:236.</a></li><li><a class="nounderline abstract_t">Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998; 66:1694.</a></li><li><a class="nounderline abstract_t">Morales JM, Campistol JM, Domínguez-Gil B, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant 2010; 10:2453.</a></li><li><a class="nounderline abstract_t">Woodside KJ, Ishihara K, Theisen JE, et al. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome. Clin Transplant 2003; 17:433.</a></li><li><a class="nounderline abstract_t">Kasprzyk T, Kwiatkowski A, Wszola M, et al. Long-term results of kidney transplantation from HCV-positive donors. Transplant Proc 2007; 39:2701.</a></li><li><a class="nounderline abstract_t">Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation 2015; 99:1192.</a></li><li><a class="nounderline abstract_t">Sibulesky L, Kling CE, Blosser C, et al. Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. Am J Transplant 2018; 18:2465.</a></li><li><a class="nounderline abstract_t">Maluf DG, Archer KJ, Mas VR. Kidney grafts from HCV-positive donors: advantages and disadvantages. Transplant Proc 2010; 42:2436.</a></li><li><a class="nounderline abstract_t">Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 2012; 60:112.</a></li><li><a class="nounderline abstract_t">Singh N, Neidlinger N, Djamali A, et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant 2012; 26:684.</a></li><li><a class="nounderline abstract_t">Cohen JB, Eddinger KC, Shelton B, et al. Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes. Clin Kidney J 2017; 10:564.</a></li><li><a class="nounderline abstract_t">Bowring MG, Shaffer AA, Massie AB, et al. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 2019; 19:2329.</a></li><li><a class="nounderline abstract_t">King KL, Husain SA, Mohan S. Trends in Transplantation Center Use of Kidneys From Deceased Donors With Positive Hepatitis C Virus Nucleic Acid Testing. Am J Kidney Dis 2020; 76:743.</a></li><li><a class="nounderline abstract_t">Lentine KL, Peipert JD, Alhamad T, et al. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360 2020; 1:1291.</a></li></ol></div><div id="topicVersionRevision">Topic 7361 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30677008" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses - United States, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29166338" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33383877" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35592445" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of Blood-Borne Viruses and Predictors of Risk in Potential Organ Donors in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32775812" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459186" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306549" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31659775" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306562" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259125" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926749" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31104346" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142940" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30040178" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943299" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Transmission of Hepatitis C Virus From Organ Donors Despite Nucleic Acid Test Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30861300" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584804" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271723" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9422419" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serologic responses to hepatitis C virus in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25091274" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatitis C virus infection and kidney transplantation in 2014: what's new?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519632" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : HIV and hepatitis C virus RNA in seronegative organ and tissue donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28060446" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36410841" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36410841" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956768" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : EASL recommendations on treatment of hepatitis C: Final update of the series☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507971" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083748" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32280841" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773693" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894697" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32843477" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35665327" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34212479" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31652392" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37441470" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Longer-Term Clinical Outcomes From the THINKER and EXPANDER Trials of Transplantation of HCV-RNA+ Donor Kidneys Into Hepatitis C Virus-Negative Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333148" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35994263" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34613666" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23919533" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688205" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27438538" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26200976" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Transplanting Hepatitis C-Positive Kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515244" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710288" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31677214" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15575906" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444217" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28712111" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7532254" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9089225" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432411" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537343" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884261" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20977636" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14703926" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021962" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term results of kidney transplantation from HCV-positive donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25340605" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29451354" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20832522" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Kidney grafts from HCV-positive donors: advantages and disadvantages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22560841" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22283142" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28852496" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30861279" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479923" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Trends in Transplantation Center Use of Kidneys From Deceased Donors With Positive Hepatitis C Virus Nucleic Acid Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33251523" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
